01218nam0 22002891i 450 UON0051746320231205105528.441978-27-11-62980-020230921d2022 |0itac50 bafreFR|||| |||||Hétérodoxes et non musulmans dans la pensée d’Abū Ḥāmid al-ĠazālīEmmanuel PisaniParisVrin2022280 p.24 cm001UON000655452001 Etudes musulmanesDirecteurs: Etienne Gilson et Louis Gardet55al-Ǧazālī, Abū Hāmid MuḥammadUONC101711FIFRParisUONL002984297.1Fonti dell'Islamismo21PISANIEmmanuelUONV2919901591139Librairie Philosophique J. VrinUONV267223650ITSOL20240220RICASIBA - SISTEMA BIBLIOTECARIO DI ATENEOUONSIUON00517463SIBA - SISTEMA BIBLIOTECARIO DI ATENEOSI VO Afr VII A 123 SI 45549 5 123 Hétérodoxes et non musulmans dans la pensée d’Abū Ḥāmid al-Ġazālī3904152UNIOR03706nam 2200793z- 450 991055738060332120220111(CKB)5400000000042093(oapen)https://directory.doabooks.org/handle/20.500.12854/76940(oapen)doab76940(EXLCZ)99540000000004209320202201d2021 |y 0engurmn|---annantxtrdacontentcrdamediacrrdacarrierSmall Cell Lung Cancer: A New Era Is Beginning?Basel, SwitzerlandMDPI - Multidisciplinary Digital Publishing Institute20211 online resource (150 p.)3-0365-2301-4 3-0365-2302-2 Small-cell lung cancer (SCLC) is the most aggressive form of lung cancer: No significant progress has been made in finding new treatments for decades and platinum-based chemotherapy has for a long time represented the standard of care. This therapeutic scenario has recently changed, thanks to positive results in terms of improvement of overall survival obtained with a combination of checkpoint inhibitors (atezolizumab or durvalumab) with platinum-etoposide in patients with extensive disease. Moreover, nivolumab and pembrolizumab showed antitumor activity and received U.S. FDA approval as single agents in patients pretreated with platinum-based therapy and at least one other therapy. The improvement in the knowledge of the biology of SCLC has led to the development of new experimental therapies that have shown promising results, including poly (ADP-ribose) polymerase (PARP) inhibitors, anti-Notch ligand Delta-like protein 3 (anti-DLL3), antibody-drug conjugates, and aurora kinase inhibitors. Future challenges are the identification of predictive biomarkers for immunotherapy, the definition of the role of new biological agents, and the improvement of integrated approached for limited disease. This Special Issue will highlight the current state of treatment of extensive SCLC, focusing on the biology of SCLC, immune-checkpoint inhibitors, PARP inhibitors, and novel cytotoxic chemotherapy and radiotherapy techniques.Small Cell Lung CancerMedicinebicsscatezolizumabbiology of SCLCchemotherapycirculating tumor cellsDDRdurvalumabextensive diseaseextensive-stage small cell lung cancergene pathwayICBimmune checkpoint inhibitorsimmune-checkpoint inhibitors in SCLCimmunotherapyImmunotherapyipilimumablobectomylurbinectedinmultimodal treatmentn/anivolumabPARPpathobiologypathology and classification of SCLCpembrolizumabpneumonectomyprognostic biomarkerradiotherapySCLCSLFN11small cell lung cancersmall-cell lung cancerSTINGsynthetic lethalitytargeted agentstargeted therapyMedicineMorabito Alessandroedt1326702Rolfo ChristianedtMorabito AlessandroothRolfo ChristianothBOOK9910557380603321Small Cell Lung Cancer: A New Era Is Beginning3037687UNINA